In September 2015, BCEC IX acquired Pharmathen from the founding family. Pharmathen is a leading European pharmaceutical company focused upon developing, manufacturing and out-licensing complex generic drugs.
Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.
The company is headquartered in Amsterdam.